RxDoctor Payments DataLook up a doctor →

Joseph Lebel, MD

Gastroenterology · Greenville, SCNPI 1790878213

Payments from drug & device makers

$22,233in general payments, 2019–2025

Across 483 payments — averaging $46.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$12K
  • Phathom Pharmaceuticals, Inc.$5K
  • Johnson & Johnson$815
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$794
  • Takeda Pharmaceuticals U.S.A., Inc.$650
  • QOL Medical, LLC$341
  • plus $3K from 25 others

What the payments were for

  • Speaking & faculty fees$13,71562%
  • Travel & lodging$7944%
  • Food & beverage$7,56934%
  • Education$1541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,233 in reported general payments places this provider in the 85th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$407,616
Medicare patients
634
Services billed
11,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase41$215,288
CreonLipase/Protease/Amylase45$125,422
RinvoqUpadacitinib12$103,075
XifaxanRifaximin26$80,910
Mesalamine59$31,496
LinzessLinaclotide39$28,995
VoqueznaVonoprazan Fumarate20$15,787
Dexlansoprazole DrDexlansoprazole16$5,689
Budesonide EcBudesonide22$4,799
Sucralfate50$3,381
Pantoprazole Sodium240$2,974
Budesonide DrBudesonide27$2,562
Esomeprazole Magnesium80$2,537
Omeprazole157$2,297
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine66$2,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Rinvoq, Linzess$11,971$257,49196 claims
Aimmune Therapeutics, Inc.Zenpep$145$215,28841 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$794$80,91026 claims
Phathom Pharmaceuticals, Inc.Voquezna$5,034$15,78720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →